SECsense Logo

Fulcrum Therapeutics 8-K Report: Key Insights from December 18, 2024 Filing

$FULC
Form 8-K
Filed on: 2024-12-23
Source
Fulcrum Therapeutics 8-K Report: Key Insights from December 18, 2024 Filing

Based on the provided section of the financial report, here are the key details and insights extracted:

  1. Company Information:
  • Name: Fulcrum Therapeutics, Inc.
  • CIK (Central Index Key): 0001680581
  • Location: 26 Landsdowne Street, Cambridge, MA 02139
  • Phone: (617) 651-8851
  1. SEC Filing Details:
  • Filing Type: 8-K (current report)
  • Filing Date: December 18, 2024
  • SEC Central File Number: 001-38978
  • EIN (Employer Identification Number): 47-4839948
  1. Stock Information:
  • Common Stock: Par value of $0.001 per share
  • Ticker Symbol: FULC
  • Exchange: NASDAQ
  1. Context and Period:
  • Period of Report: The report covers a single day, December 18, 2024.

Insights:

  • The filing indicates that Fulcrum Therapeutics is maintaining compliance with SEC regulations by submitting an 8-K, which is typically used to report major events that shareholders should know about.
  • The company's listing on NASDAQ under the ticker FULC suggests that it is publicly traded, which provides liquidity and potentially access to capital markets.
  • The specific date of the report suggests it might be related to a significant corporate event or announcement happening on that day.

Overall, the report serves to inform stakeholders about the company's activities, financial health, or other relevant events occurring at the time of the filing. Further details from the complete 8-K filing would be necessary to gain deeper insights into the specific content of the report.